Allergan Aesthetics, an AbbVie company listed on NYSE:ABBV, issued a press release on November 3, 2026, announcing nine abstract presentations at the 2026 American Society for Dermatologic Surgery Annual Meeting, scheduled for November 5-8 in San Diego.

Key Highlights

  • Nine abstracts scheduled: Allergan Aesthetics disclosed nine presentations across categories including medical weight loss, neurotoxin innovation, skincare and exosomes, and body contouring.
  • Phase 4 weight loss research: Two video oral abstract presentations will share new data from Phase 4 studies examining aesthetic treatment in patients taking GLP-1-related medications for weight loss, with a focus on patient satisfaction and psychosocial outcomes.
  • Top Ten session inclusion: A digital image analysis comparing investigational trenibotulinumtoxinE (trenibotE) and BOTOX Cosmetic (onabotulinumtoxinA) for glabellar line severity and brow position will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session at 7:30 a.m. PT on Sunday, November 8.
  • Expert panel on consumer expectations: An expert panel titled "The Aesthetics Evolution: Inside the Changing Consumer Landscape" is scheduled for 12:30 p.m. PT on Thursday, November 5, drawing on the company's "What Consumers Really Want" report.
  • Exosome skincare data: Four video oral abstract presentations will cover a topical cosmetic human fibroblast-derived exosome serum used as part of a daily skincare regimen and alongside in-office procedures including radiofrequency microneedling, non-ablative laser, and diamond tip microdermabrasion.
  • Body contouring sequence study: One presentation will address how treatment sequence may influence outcomes when combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.

Allergan Aesthetics Highlights Research Scope Across Six Aesthetic Categories at ASDS 2026

According to the filing, Allergan Aesthetics will present research spanning six categories at the 2026 ASDS Annual Meeting. The company disclosed that two Phase 4 studies focus specifically on patients undergoing medical weight loss with GLP-1-related medications, examining changes in facial appearance, skin quality, patient satisfaction, and psychosocial outcomes. One study, titled "HARMONY IN DIVERSITY," addresses multimodal aesthetic treatment in a medical weight loss cohort, while a second examines outcomes following hyaluronic acid injectable treatment in the same patient population.

The filing quoted Darin Messina, Ph.D., senior vice president and head of aesthetics research and development at AbbVie, as saying: "Advancing aesthetic medicine starts with understanding patients' evolving needs and generating the scientific evidence to keep pace." The filing also quoted study investigator Joely Kaufman-Janette, M.D., stating that examining "patient satisfaction and psychosocial well-being alongside changes in physical appearance" provides "a more complete picture of their needs." The digital image analysis on trenibotE and onabotulinumtoxinA, to be presented during the Top Ten session, uses "objective digital imaging to add quantitative measures that complement clinician assessment," according to the filing. That presentation is attributed to Shannon Humphrey, M.D., and will be delivered by Jean Carruthers, M.D.

The filing listed all nine presentations by title, authors, and format. Eight are classified as video oral abstracts, and one - the trenibotE digital image analysis - is classified as an oral presentation. Authors across the presentations include researchers and physicians from multiple institutions, alongside Allergan Aesthetics scientists listed by name and credential in the filing.

What Was Disclosed

Allergan Aesthetics disclosed the titles, formats, authors, and scheduling details for nine abstracts to be presented at the 2026 ASDS Annual Meeting in San Diego, covering GLP-1-related medical weight loss aesthetics, neurotoxin comparison, exosome skincare, multimodal facial treatment, and body contouring.